{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicqhdjfcjnfe3skly7sms5wnx723ldmm5azsxa3d532w3qozvjeia",
    "uri": "at://did:plc:k7h5fn3kdhjpj37pc6yhno2o/app.bsky.feed.post/3mfs6ysltje22"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiftzp6gdabwua2tst2wixvfq4s7mykoijkbum5lnjwqzyjbu3obv4"
    },
    "mimeType": "image/jpeg",
    "size": 34859
  },
  "path": "/article/head-to-head-trial-shows-eli-lillys-oral-glp-1-orforglipron-outperforms-oral/",
  "publishedAt": "2026-02-26T21:50:00.000Z",
  "site": "https://www.scientificamerican.com",
  "textContent": "A new trial found that Eli Lilly’s GLP-1 pill resulted in greater reductions in blood sugar levels and weight than oral semaglutide did, but fewer people stayed on it",
  "title": "Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide"
}